Renaissance Technologies LLC Sells 76,350 Shares of Kamada Ltd. $KMDA

Renaissance Technologies LLC cut its position in Kamada Ltd. (NASDAQ:KMDA) by 9.1% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 762,948 shares of the biotechnology company’s stock after selling 76,350 shares during the quarter. Renaissance Technologies LLC owned about 1.33% of Kamada worth $6,363,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also recently bought and sold shares of the company. Aristides Capital LLC boosted its holdings in Kamada by 4.5% in the 1st quarter. Aristides Capital LLC now owns 34,491 shares of the biotechnology company’s stock valued at $288,000 after purchasing an additional 1,476 shares during the period. NewEdge Advisors LLC raised its position in shares of Kamada by 9.2% in the fourth quarter. NewEdge Advisors LLC now owns 57,538 shares of the biotechnology company’s stock worth $406,000 after buying an additional 4,870 shares in the last quarter. XTX Topco Ltd bought a new stake in shares of Kamada during the 4th quarter valued at about $103,000. Quadrature Capital Ltd boosted its holdings in shares of Kamada by 53.5% in the 4th quarter. Quadrature Capital Ltd now owns 21,889 shares of the biotechnology company’s stock worth $155,000 after purchasing an additional 7,627 shares in the last quarter. Finally, Man Group plc boosted its stake in Kamada by 19.9% in the fourth quarter. Man Group plc now owns 34,294 shares of the biotechnology company’s stock worth $242,000 after buying an additional 5,684 shares in the last quarter. 20.38% of the stock is owned by institutional investors.

Kamada Stock Up 1.5%

NASDAQ:KMDA opened at $7.34 on Wednesday. The stock has a market cap of $422.12 million, a P/E ratio of 20.97, a price-to-earnings-growth ratio of 0.66 and a beta of 0.86. The firm’s fifty day simple moving average is $7.29 and its 200 day simple moving average is $8.01. Kamada Ltd. has a twelve month low of $6.50 and a twelve month high of $9.35.

Kamada (NASDAQ:KMDA) last issued its quarterly earnings data on Thursday, May 14th. The biotechnology company reported $0.07 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.12 by ($0.05). Kamada had a net margin of 11.21% and a return on equity of 7.73%. The company had revenue of $45.24 million for the quarter, compared to analysts’ expectations of $46.72 million. On average, analysts expect that Kamada Ltd. will post 0.44 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts have weighed in on the company. William Blair set a $15.00 price objective on Kamada in a research report on Tuesday, July 21st. Wall Street Zen downgraded shares of Kamada from a “buy” rating to a “hold” rating in a research note on Saturday, May 23rd. Weiss Ratings lowered shares of Kamada from a “buy (b)” rating to a “buy (b-)” rating in a report on Thursday, June 25th. Finally, Benchmark reiterated a “buy” rating on shares of Kamada in a report on Tuesday, July 21st. Three investment analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and an average price target of $13.00.

Kamada Company Profile

Kamada Ltd. is a biopharmaceutical company headquartered in Israel that specializes in the development, manufacturing and commercialization of plasma?derived protein therapeutics. The company focuses on treatments for rare and serious diseases, leveraging its proprietary fractionation and purification technologies to produce purified human proteins. Kamada’s product portfolio addresses critical therapeutic areas in immunology, hematology and pulmonology, where alternative treatment options may be limited.

Among Kamada’s marketed products is Glassia®, an alpha?1 antitrypsin augmentation therapy approved by the U.S.